Label-Free Characterization and Quantification of Mucosal Inflammation in Common Murine Colitis Models With Multiphoton Imaging

Autor: Lucas Kreiss, Oana-Maria Thoma, Sarah Lemire, Kristina Lechner, Birgitta Carlé, Ashwathama Dilipkumar, Timo Kunert, Kristina Scheibe, Christina Heichler, Anna-Lena Merten, Benno Weigmann, Clemens Neufert, Kai Hildner, Michael Vieth, Markus F Neurath, Oliver Friedrich, Sebastian Schürmann, Maximilian J Waldner
Rok vydání: 2021
Předmět:
Zdroj: Inflammatory bowel diseases. 28(11)
ISSN: 1536-4844
Popis: BackgroundClinical challenges in inflammatory bowel diseases require microscopic in vivo evaluation of inflammation. Here, label-free imaging holds great potential, and recently, our group demonstrated the advantage of using in vivo multiphoton endomicroscopy for longitudinal animal studies. This article extends our previous work by in-depth analysis of label-free tissue features in common colitis models quantified by the multiphoton colitis score (MCS).MethodsFresh mucosal tissues were evaluated from acute and chronic dextran sulfate sodium (DSS), TNBS, oxazolone, and transfer colitis. Label-free imaging was performed by using second harmonic generation and natural autofluorescence. Morphological changes in mucosal crypts, collagen fibers, and cellularity in the stroma were analyzed and graded.ResultsOur approach discriminated between healthy (mean MCS = 2.5) and inflamed tissue (mean MCS > 5) in all models, and the MCS was validated by hematoxylin and eosin scoring of the same samples (85.2% agreement). Moreover, specific characteristics of each phenotype were identified. While TNBS, oxazolone, and transfer colitis showed high cellularity in stroma, epithelial damage seemed specific for chronic, acute DSS and transfer colitis. Crypt deformations were mostly observed in acute DSS.ConclusionsQuantification of label-free imaging is promising for in vivo endoscopy. In the future, this could be valuable for monitoring of inflammatory pathways in murine models, which is highly relevant for the development of new inflammatory bowel disease therapeutics.
Databáze: OpenAIRE